Compare ImmunityBio Inc. Common Stock (IBRX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs KB Financial Group, Inc. — how do they compare? ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.51B), while KB Financial Group, Inc. trades at $121.96 (market cap $44.15B). The key difference: KB Financial Group, Inc. is far larger — about 4.2× ImmunityBio Inc. Common Stock's market cap, and KB Financial Group, Inc. pays a 2.65% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and KB Financial Group, Inc. for 33 Days on average.
| IBRX | KB | |
|---|---|---|
Market Cap | $10.51B | $44.15B |
Volume | 10,445,785 | 131,395 |
Sector | Health | Financials |
52-Week High | $11.55 | $132.88 |
52-Week Low | $1.98 | $77.50 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $10.97B | $215.53T |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KB Financial Group trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock exhibits neutral technical signals while maintaining strong fundamental performance with consistent earnings beats and improving profitability. Recent quarterly results exceeded expectations, with Q2 2026 EPS of $3.79 beating estimates of $3.51. The company demonstrates solid revenue growth, climbing from $17.77T in 2022 to $21.23T in 2025, with net income margins expanding to 27.47%.
KB presents an attractive value proposition with a P/E of 9.92 and P/B of 0.97, trading below book value. Analyst sentiment is mixed with 33% buy ratings but strong institutional interest. Key risks include banking sector volatility and interest rate sensitivity, while opportunities lie in South Korea's outperforming market and the company's expanding non-banking activities driving fee income growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
